利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN105998153B 猴耳环提取物在制备抗产超广谱β-内酰胺酶大肠杆菌药物中的应用 有权 转让

猴耳环提取物在制备抗产超广谱β-内酰胺酶大肠杆菌药物中的应用
摘要：
本发明公开了猴耳环提取物在制备抗产超广谱β‑内酰胺酶大肠杆菌药物中的应用。并进一步公开猴耳环提取物在制备抗生素抗产超广谱β‑内酰胺酶大肠杆菌增敏药物中的应用。尤其是作为阿米卡星和复方新诺明抗产超广谱β‑内酰胺酶大肠杆菌增敏药物中的应用。经试验证明，猴耳环提取物与阿米卡星或复方新诺明联用均呈协同作用。在本发明猴耳环提取物小于等于1/2MIC时联用，比阿米卡星单用用量降低75％；比复方新诺明单用用量降低99.3％。可作为天然的抗菌药物或抗生素增敏剂，应用于由产ESBL大肠杆菌引起的疾病治疗。为解决该类抗生素的耐药性问题提供了新的途径和替代药物。
摘要（英）：

The invention discloses application of pithecellobium clypearia extract to preparation of a drug for resisting generation of extended spectrum beta-lactamase (ESBL) escherichia coli, further discloses application of pithecellobium clypearia extract to preparation of a sensibilization drug for resisting generation of extended spectrum beta-lactamase escherichia coli with antibiotics, and particularly relates to application to a drug for resisting generation of extended spectrum beta-lactamase escherichia coli as amikacin and sulfamethoxazole. It is proved through tests that the pithecellobium clypearia extract and amikacin or sulfamethoxazole take the synergistic effect when combined. The pithecellobium clypearia extract is combined when smaller than or equal to 1/2MIC, and the usage is lower than that of amikacin used singly by 75% and is lower than that of sulfamethoxazole used singly by 99.3%. The drug can be used as a natural antibacterial drug or antibiotic sensitizer and is applied to treat diseases caused by generation of ESBL escherichia coli. A new path and a substitute drug are provided for solving the drug resistance problem of the antibiotics.

公开/授权文献
0/0